Immunext

Description

• ImmuNext is developing immune-based therapeutics to treat patients with immune-related disorders, including autoimmunity, cancer, transplantation rejection, and infectious disease. We are targeting critical immunomodulatory molecules that either promote or suppress immune responses to restore immune homeostasis and cure disease. Using antibody-based therapeutics, a spectrum of newly identified molecules are being targeted to achieve disease remission.Our core competencies are discovery, target biology and pre-clinical drug development.ImmuNext assets:* Anti-VISTA, a negative checkpoint regulator antagonist for the treatment of cancer, is in the clinic. Partnered with Johnson and Johnson subsidiary, Janssen Biotech, in September, 2012. * VISTA agonists for the treatment of autoimmune disease. Partnered with Hoffman-La Roche in December, 2016, ImmuNext is developing antibodies to VISTA to suppress immune response in multiple inflammatory diseases. The impact of these antibodies is due to the direct suppression of immune cells leading to immune suppression and long term tolerance. This represents a new class of checkpoint inhibitor agonists with broad utility in immunotherapy.* Anti-CD40L antagonists, re-engineered for safety and efficacy. Anti-CD40L was partnered with Sanofi in January, 2017. CD40L (CD154) is a highly validated, superlative therapeutic target in autoimmunity and graft rejection. Dr. Noelle, who discovered CD40L, has re-engineered antagonist antibodies to avoid thromboembolic concerns while maintaining efficacy. *Other programs include a CD40 agonist for neoantigen cancer vaccines and a novel immuno-metabolic target, in each case establishing new classes of compounds.More: Portfolio - http://immunext.com/portfolio/Careers - http://immunext.com/careers/
• 

  Headquarters:1 Medical Center Dr , Lebanon, New Hampshire, United States

  More
• 

  Phone Number: +1 802-649-8109

• 

  Website: http://immunext.com/

• 

  Employees:11

• 

  Revenue:$10 - 50M

• 

  Legal Name:Immunext

• Immunext's Social Media

  
• Is this data correct?

• |  NAICS Code: 541713  |

  Show More